New insights show ASCL1's role in neuroendocrine prostate cancer, an aggressive and treatment-resistant type
A scientist whose discoveries about prostate cancer have led to lifesaving treatments is now shedding light on an emerging and deadlier form of the disease: neuroendocrine prostate cancer (NEPC).